Sanofi (SAN:CA) Q1 2026 Earnings Call April 23, 2026 7:00 AM EDT
Company Participants
Thomas Larsen - Head of Investor Relations & General Medicines
Olivier Charmeil - Interim CEO & Executive VP of General Medicines
François-Xavier Roger - Executive VP & CFO
Houman Ashrafian - Executive VP & Head of Research & Development
Manuela Buxo - Executive VP & Head of Specialty Care
Roy Papatheodorou - Executive VP & General Counsel
Conference Call Participants
James Gordon - Barclays Bank PLC, Research Division
Florent Cespedes
Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division
Steve Scala - TD Cowen, Research Division
Sachin Jain - BofA Securities, Research Division
Richard Vosser - JPMorgan Chase & Co, Research Division
Sarita Kapila - Morgan Stanley, Research Division
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Graham Glyn Parry - Citigroup Inc., Research Division
Peter Verdult - BNP Paribas, Research Division
David Risinger - Leerink Partners LLC, Research Division
Matthew Weston - UBS Investment Bank, Research Division
Simon Baker - Rothschild & Co Redburn, Research Division
Rajesh Kumar - HSBC Global Investment Research
Presentation
Thomas Larsen
Head of Investor Relations & General Medicines
Hello, everyone. This is Thomas Larsen from the Sanofi IR team. Welcome to the First Quarter 2026 conference call for investors and analysts. As usual, you will find the slides on sanofi.com.
Please turn to Slide #3. Here, we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our new Form 20-F on file with the U.S. SEC since February in our French Universal Registration Document for a description of these risk factors. As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。